BP and Verenium form jv to deliver advan
๐
Article
๐
2009
๐
Elsevier Science
โ 59 KB
In view of the economic environment, Novozymes considers its current 2009 growth outlook satisfactory. The slowdown in 4Q 2008 is not considered a reliable indicator of 2009 full-year performance. Sales growth is forecast at 8-13% (in terms of DKR), and operating profit is expected to grow by 10-15%